BR9006264A - Derivados de aminoacidos e processo para a sua producao,medicamentos,usos de um derivado de aminoacido e processo para tratamento ou prevencao de infeccoes viroticas - Google Patents

Derivados de aminoacidos e processo para a sua producao,medicamentos,usos de um derivado de aminoacido e processo para tratamento ou prevencao de infeccoes viroticas

Info

Publication number
BR9006264A
BR9006264A BR909006264A BR9006264A BR9006264A BR 9006264 A BR9006264 A BR 9006264A BR 909006264 A BR909006264 A BR 909006264A BR 9006264 A BR9006264 A BR 9006264A BR 9006264 A BR9006264 A BR 9006264A
Authority
BR
Brazil
Prior art keywords
amino acid
infections
virotic
drugs
treating
Prior art date
Application number
BR909006264A
Other languages
English (en)
Portuguese (pt)
Inventor
Joseph Armstrong Martin
Sally Redshaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9006264A publication Critical patent/BR9006264A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Confectionery (AREA)
  • Measurement Of Force In General (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cleaning Or Clearing Of The Surface Of Open Water (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR909006264A 1989-12-11 1990-12-10 Derivados de aminoacidos e processo para a sua producao,medicamentos,usos de um derivado de aminoacido e processo para tratamento ou prevencao de infeccoes viroticas BR9006264A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898927913A GB8927913D0 (en) 1989-12-11 1989-12-11 Amino acid derivatives
SG120493A SG120493G (en) 1989-12-11 1993-11-02 N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof

Publications (1)

Publication Number Publication Date
BR9006264A true BR9006264A (pt) 1991-09-24

Family

ID=26296345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR909006264A BR9006264A (pt) 1989-12-11 1990-12-10 Derivados de aminoacidos e processo para a sua producao,medicamentos,usos de um derivado de aminoacido e processo para tratamento ou prevencao de infeccoes viroticas

Country Status (48)

Country Link
US (1) US5196438A (cg-RX-API-DMAC10.html)
EP (1) EP0432695B1 (cg-RX-API-DMAC10.html)
JP (1) JP2807093B2 (cg-RX-API-DMAC10.html)
KR (1) KR970005912B1 (cg-RX-API-DMAC10.html)
CN (2) CN1034805C (cg-RX-API-DMAC10.html)
AT (1) ATE122661T1 (cg-RX-API-DMAC10.html)
AU (1) AU634319B2 (cg-RX-API-DMAC10.html)
BG (1) BG51452A3 (cg-RX-API-DMAC10.html)
BR (1) BR9006264A (cg-RX-API-DMAC10.html)
CA (1) CA2030433C (cg-RX-API-DMAC10.html)
CU (1) CU22305A3 (cg-RX-API-DMAC10.html)
CZ (1) CZ280558B6 (cg-RX-API-DMAC10.html)
DE (2) DE69019481T2 (cg-RX-API-DMAC10.html)
DK (1) DK0432695T3 (cg-RX-API-DMAC10.html)
DZ (1) DZ1467A1 (cg-RX-API-DMAC10.html)
EG (1) EG19722A (cg-RX-API-DMAC10.html)
ES (1) ES2072959T3 (cg-RX-API-DMAC10.html)
FI (2) FI973895A7 (cg-RX-API-DMAC10.html)
GB (2) GB8927913D0 (cg-RX-API-DMAC10.html)
GR (1) GR3017114T3 (cg-RX-API-DMAC10.html)
HK (1) HK129093A (cg-RX-API-DMAC10.html)
HR (1) HRP930341B1 (cg-RX-API-DMAC10.html)
HU (2) HU207298B (cg-RX-API-DMAC10.html)
ID (1) ID1018B (cg-RX-API-DMAC10.html)
IE (1) IE67523B1 (cg-RX-API-DMAC10.html)
IL (1) IL96550A (cg-RX-API-DMAC10.html)
IN (1) IN172553B (cg-RX-API-DMAC10.html)
IS (1) IS1803B (cg-RX-API-DMAC10.html)
LT (1) LT3682B (cg-RX-API-DMAC10.html)
LU (1) LU90014I2 (cg-RX-API-DMAC10.html)
LV (1) LV5738B4 (cg-RX-API-DMAC10.html)
MA (1) MA22014A1 (cg-RX-API-DMAC10.html)
MC (1) MC2195A1 (cg-RX-API-DMAC10.html)
MT (1) MTP1075B (cg-RX-API-DMAC10.html)
MW (1) MW8890A1 (cg-RX-API-DMAC10.html)
MX (1) MX173630B (cg-RX-API-DMAC10.html)
NL (1) NL970013I2 (cg-RX-API-DMAC10.html)
NO (1) NO176566C (cg-RX-API-DMAC10.html)
OA (1) OA09334A (cg-RX-API-DMAC10.html)
PL (1) PL165225B1 (cg-RX-API-DMAC10.html)
PT (1) PT96145B (cg-RX-API-DMAC10.html)
RO (1) RO107942B1 (cg-RX-API-DMAC10.html)
RU (1) RU2071470C1 (cg-RX-API-DMAC10.html)
SG (1) SG120493G (cg-RX-API-DMAC10.html)
SI (1) SI9012315B (cg-RX-API-DMAC10.html)
SK (1) SK576590A3 (cg-RX-API-DMAC10.html)
ZA (1) ZA909743B (cg-RX-API-DMAC10.html)
ZW (1) ZW17490A1 (cg-RX-API-DMAC10.html)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
ES2112880T3 (es) * 1991-11-08 1998-04-16 Merck & Co Inc Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
WO1993018006A1 (en) 1992-03-11 1993-09-16 Narhex Limited Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
ES2066623T3 (es) * 1992-03-13 1995-03-01 Bio Mega Boehringer Ingelheim Derivados sustituidos del acido pipecolinico como inhibidores de la vih-proteasa.
EP0957093A3 (en) * 1992-05-21 2000-04-12 Monsanto Company Retrovial protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
ES2177868T3 (es) 1992-08-25 2002-12-16 Searle & Co Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5693815A (en) * 1993-01-17 1997-12-02 Schering Corporation Peptides
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
EP0738724B1 (de) * 1993-07-15 1998-11-04 F. Hoffmann-La Roche Ag Verfahren zur Herstellung eines N-tert.Butylamids
BR9408531A (pt) * 1994-02-02 1997-08-05 Lilly Co Eli Inibidores da protease hiv e intermediários
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
IL122353A0 (en) * 1995-06-06 1998-04-05 Hoffmann La Roche Pharmaceutical compositions comprising proteinase inhibitor and a monoglyceride
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU759386B2 (en) * 1995-06-29 2003-04-10 Abbvie Inc. Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
ATE299707T1 (de) 1995-11-13 2005-08-15 Vitaleech Bioscience N V Antivirale isolate von blutegeln
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
EP0823424A1 (de) * 1996-08-09 1998-02-11 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Chinargin
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ATE236880T1 (de) 1996-12-11 2003-04-15 Hoffmann La Roche Verfahren zur herstellung gemischter anhydride
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2779653B1 (fr) 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
ES2235492T3 (es) * 1998-06-19 2005-07-01 Vertex Pharmaceuticals Incorporated Inhibidores de aspartil proteasa de tipo sulfonamida.
US6509468B1 (en) * 1998-10-21 2003-01-21 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
KR100277723B1 (ko) 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
SK286305B6 (en) * 1999-06-04 2008-07-07 Abbott Laboratoires Improved pharmaceutical formulations comprising ritonavir
WO2001005230A1 (en) * 1999-07-20 2001-01-25 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
AU777824B2 (en) 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
IT1313682B1 (it) * 1999-11-25 2002-09-09 Archimica Spa Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
ES2304990T3 (es) 2000-01-19 2008-11-01 Abbott Laboratories Formulaciones farmaceuticas de inhibidores de la proteasa del vih mejoradas.
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US7087418B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
EP1515944A1 (en) * 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
WO2005004836A2 (en) * 2003-07-11 2005-01-20 F.Hoffmann-La Roche Ag Saquinavir mesylate oral dosage form
EP1604662A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
US8318701B2 (en) 2004-07-27 2012-11-27 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
WO2006134612A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited A process for the preparation of saquinavir using novel intermediate
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
CN103480000A (zh) * 2007-06-29 2014-01-01 吉里德科学公司 治疗用组合物和方法
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
US20100093811A1 (en) * 2007-09-25 2010-04-15 Coburn Craig A Hiv protease inhibitors
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
EP2376514A2 (en) * 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
US8716262B2 (en) * 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010138338A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
EP2392926A1 (en) 2011-02-09 2011-12-07 Roche Diagnostics GmbH Urinary biomarkers in HIV infected subjects
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
US9233943B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
WO2014043019A1 (en) 2012-09-11 2014-03-20 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2912047B1 (en) 2012-10-29 2016-08-24 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
EP3083609B1 (en) 2013-12-19 2018-08-15 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US9994587B2 (en) 2014-03-06 2018-06-12 Merck Sharp & Dohme Corp. HIV protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933968A (en) * 1960-10-26 1963-08-14 May & Baker Ltd New phthalimide derivatives
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
US3901897A (en) * 1972-10-05 1975-08-26 Squibb & Sons Inc 1,2,3,4,4a,5,6,7-octahydro-7-aryl-isoquinolines and derivatives thereof
US4329473A (en) * 1979-06-01 1982-05-11 Almquist Ronald G Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
SE421551B (sv) * 1980-03-26 1982-01-04 Sandvik Ab Borrverktyg for rotations- och/eller slagborrning
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (en) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
WO1988000939A1 (fr) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Derives d'amino-alcools optiquement actifs et procede pour leur preparation
EP0264106B1 (en) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
DE4033062A1 (de) * 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols

Also Published As

Publication number Publication date
FI905983L (fi) 1991-06-12
SI9012315B (sl) 1998-06-30
CN1138983A (zh) 1997-01-01
CN1066329C (zh) 2001-05-30
MX23619A (es) 1993-10-01
DE69019481D1 (de) 1995-06-22
RO107942B1 (ro) 1994-01-31
DE19675051I2 (de) 2001-04-12
FI100883B (fi) 1998-03-13
NO176566B (no) 1995-01-16
IL96550A0 (en) 1991-09-16
CN1052482A (zh) 1991-06-26
HU211342A9 (en) 1995-11-28
OA09334A (fr) 1992-09-15
CZ576590A3 (en) 1995-11-15
EP0432695B1 (en) 1995-05-17
NL970013I2 (nl) 1997-09-01
MTP1075B (en) 1991-07-31
MC2195A1 (fr) 1992-10-05
NL970013I1 (nl) 1997-05-01
LU90014I2 (fr) 1997-01-31
NO176566C (no) 1995-04-26
HK129093A (en) 1993-12-03
MX173630B (es) 1994-03-18
CA2030433C (en) 1997-10-21
CZ280558B6 (cs) 1996-02-14
PT96145B (pt) 1998-04-30
DE69019481T2 (de) 1995-11-09
IE67523B1 (en) 1996-04-03
PT96145A (pt) 1991-09-30
KR970005912B1 (en) 1997-04-22
MW8890A1 (en) 1991-03-13
US5196438A (en) 1993-03-23
AU634319B2 (en) 1993-02-18
JPH03255076A (ja) 1991-11-13
ES2072959T3 (es) 1995-08-01
EP0432695A2 (en) 1991-06-19
ID1018B (id) 1996-10-18
IE904453A1 (en) 1991-06-19
PL165225B1 (pl) 1994-11-30
HRP930341B1 (en) 1998-12-31
CU22305A3 (es) 1995-01-31
CN1034805C (zh) 1997-05-07
CA2030433A1 (en) 1991-06-12
SG120493G (en) 1994-01-21
NO905322L (no) 1991-06-12
GB2239016A (en) 1991-06-19
EP0432695A3 (en) 1991-12-18
LT3682B (en) 1996-01-25
HU908076D0 (en) 1991-06-28
FI973895L (fi) 1997-10-06
IL96550A (en) 1995-03-15
GB8927913D0 (en) 1990-02-14
GR3017114T3 (en) 1995-11-30
IS3651A7 (is) 1991-06-12
EG19722A (en) 1996-01-31
SI9012315A (en) 1997-10-31
NO905322D0 (no) 1990-12-10
DZ1467A1 (fr) 2004-09-13
HRP930341A2 (en) 1994-10-31
SK280249B6 (sk) 1999-10-08
GB2239016B (en) 1993-08-04
AU6787690A (en) 1991-06-13
ZA909743B (en) 1991-08-28
ZW17490A1 (en) 1992-06-17
HUT56073A (en) 1991-07-29
JP2807093B2 (ja) 1998-09-30
SK576590A3 (en) 1999-10-08
ATE122661T1 (de) 1995-06-15
GB9026776D0 (en) 1991-01-30
LTIP862A (en) 1995-03-27
LV5738B4 (lv) 1996-12-20
BG51452A3 (bg) 1993-05-14
MA22014A1 (fr) 1991-07-01
RU2071470C1 (ru) 1997-01-10
FI905983A0 (fi) 1990-12-04
KR910011894A (ko) 1991-08-07
FI973895A0 (fi) 1997-10-06
DK0432695T3 (da) 1995-09-11
HU207298B (en) 1993-03-29
IN172553B (cg-RX-API-DMAC10.html) 1993-09-25
LV5738A4 (lv) 1996-08-20
IS1803B (is) 2002-02-26
PL288201A1 (en) 1991-09-09
FI973895A7 (fi) 1997-10-06

Similar Documents

Publication Publication Date Title
BR9006264A (pt) Derivados de aminoacidos e processo para a sua producao,medicamentos,usos de um derivado de aminoacido e processo para tratamento ou prevencao de infeccoes viroticas
BR9406503A (pt) Combinação de compostos composição farmacêutica e processos para tratar aids para evitar e para tratar infecção por HIV e para inibir protease de HIV
NO933199L (no) Heteroarenylpiperaziner, fremgangsmåte for deres fremstilling og anvendelse derav som legemidler
MY111630A (en) Amino acid derivatives.
ECSP900707A (es) Derivados de aminoacidos

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FC Decision: refusal
CKFC Appeal: appeal against refusal